A 'Polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America

Health Affairs

Volumn 32, Issue 1, 2013, Pages 155-164

  Bautista, Leonelo E ^a   Vera Cala, Lina M ^b   Ferrante, Daniel ^c   Herrera, Víctor M ^d   Miranda, J Jaime ^e   Pichardo, Rafael ^f   Sánchez Abanto, José R ^g   Ferreccio, Catterina ^h   Silva, Eglé ⁱ   Arenas, Myriam Oróstegui ^b   Chirinos, Julio A ^j   Medina Lezama, Josefina ^k   Pérez, Cynthia M ^l   Schapochnik, Norberto ^m   Casas, Juan P ⁿ  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^c Ministerio de Salud y Ambiente ^*  (Argentina)

^d UNIVERSIDAD AUTÓNOMA DE BUCARAMANGA   (Colombia)

^e UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^f Instituto dominicano de Cardiología   (Dominican Republic)

^g INSTITUTO NACIONAL DE SALUD   (Peru)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

ⁱ UNIVERSIDAD DEL ZULIA   (Venezuela)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSIDAD NACIONAL DE SAN AGUSTÍN DE AREQUIPA   (Peru)

^l UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^m Universidad Nacional de Lanus   (Argentina)

ⁿ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIGH RISK PATIENT; PRIMARY PREVENTION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOUTH AND CENTRAL AMERICA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANTIHYPERTENSIVE AGENTS; ASPIRIN; ATENOLOL; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LATIN AMERICA; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIMVASTATIN; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84872083289     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0948     Document Type: Article

References (38)

1. Perel P, Casas JP, Ortiz Z, Miranda JJ. Noncommunicable diseases and injuries in Latin America and the Caribbean: time for action. PLoS Med. 2006;3(9):e344.
2. Anderson GF. Missing in action: international aid agencies in poor countries to fight chronic disease. Health Aff (Millwood). 2009; 28(1):202-5.
3. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360(9326):2-3.
4. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404): 1419.
5. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006; 368(9536):679-86.
6. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672): 1341-51.
7. Bautista LE, Casas JP, Herrera VM, Miranda JJ, Perel P, Pichardo R, et al. The Latin American Consortium of Studies in Obesity (LASO). Obes Rev. 2009;10(3): 364-70.
8. To access the Appendix, click on the Appendix link in the box to the right of the article online
9. Musgrove P, Fox-Rushby J. Costeffectiveness analysis for priority setting. Chapter 15 in: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. New York (NY): Oxford University Press; 2006. p. 271-85.
10. World Health Organization. Physical status: the use and interpretation of anthropometry-report of a WHO expert committee. Geneva: WHO; 1995. (WHO Technical Report Series No. 854).
11. Herrera VM, Casas JP, Miranda JJ, Perel P, Pichardo R, González A, et al. Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease. Int J Obes (Lond). 2009;33(5):568-76.
12. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr., Lenfant C, National Heart, Lung, and Blood Institute, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13-8.
13. D'Agostino RB Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6): 743-53.
14. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press; 1996.
15. D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-7.
16. Jiménez-Corona A, López-Ridaura R, Williams K, González-Villalpando ME, Simón J, González-Villalpando C. Applicability of Framingham risk equations for studying a low-income Mexican population. Salud Publica Mex. 2009;51(4):298-305.
17. Clayton TC, Lubsen J, Pocock SJ, Voko Z, Kirwan BA, Fox KA, et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ. 2005;331(7521):869.
18. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med. 2002;162(21):2405-10.
19. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2(8607):349-60.
20. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Five-year survival after firstever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke. 2000;31(9): 2080-6.
21. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke. 2003;34(8):1842-6.
22. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke. 2004;35(3):731-5.
23. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370(9604):2054-62.
24. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-STelevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-42.
25. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998;98(18):1860-8.
26. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-157.
27. Fox KAA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, et al. Management of acute coronary syndromes. Variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002; 23(15):1177-89.
28. Orlandini A, Díaz R, Wojdyla D, Pieper K, Van deWerf F, Granger CB, et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006;27(5): 527-33.
29. Gold MR, Siegel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
30. Laxminarayan R, Chow J, Shahid-Salles SA. Intervention cost-effectiveness: overview of main messages. Chapter 2 in: Jamison DT, Breman JG, MeashamAR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. New York (NY): Oxford University Press; 2006. p. 35-86.
31. Sorensen S, Engelgau M, Hoerger T, Hicks K, Narayan K, Williamson D. Assessment of the benefits from a polypill to reduce cardiovascular disease among persons with type 2 diabetes mellitus. Poster presented at: 64th Annual Scientific Sessions of the American Diabetes Association, Orlando, Florida, 2004 Jun 4-8.
32. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development [Internet]. Geneva: World Health Organization; 2001 [cited 2012 Nov 30]. Available from: http://whqlibdoc.who.int/ publications/2001/924154550x.pdf
33. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361(9359):717-25.
34. World Bank. Gross national income per capita 2010, Atlas method and PPP [Internet]. Washington (DC): World Bank; 2009 Jul 10 [cited 2012 Dec 5]. Available from: http:// siteresources.worldbank.org/ DATASTATISTICS/Resources/ GNIPC.pdf
35. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99-109.
36. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15): 2051-7.
37. Rubinstein A, García Martí S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009;7:10.
38. Rubinstein A, Colantonio L, Bardach A, Caporale J, Martí SG, Kopitowski K, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and costeffectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627.